High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: A feasibility study

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Liu, Yue E ^a   Lin, Qiang ^a   Meng, Fan Jie ^a   Chen, Xue Ji ^a   Ren, Xiao Cang ^a   Cao, Bin ^a   Wang, Na ^a   Zong, Jie ^a   Peng, Yu ^a   Ku, Ya Jun ^a   Chen, Yan ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Accelerated hypofractionated radiotherapy; Carboplatin; Concurrent chemoradiotherapy; Non small cell lung cancer; Three dimensional conformal radiotherapy; Vinorelbine

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 11; LIDOCAINE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DYSPHAGIA; ESOPHAGITIS; FEASIBILITY STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL SUPPORT; ODYNOPHAGIA; PLASMA CONCENTRATION-TIME CURVE; PROSPECTIVE STUDY; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION PNEUMONIA; REHYDRATION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THREE DIMENSIONAL IMAGING; TREATMENT DURATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEASIBILITY STUDIES; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RECURRENCE; VINBLASTINE;

EID: 84881181636     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-198     Document Type: Article

References (43)

1. Stinchcombe TE, Bogart JA. Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Oncologist 2012, 17:682-693. 10.1634/theoncologist.2012-0020, 3360908, 22531360.
2. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: seven year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996, 88:1210-1215. 10.1093/jnci/88.17.1210, 8780630.
3. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2181-90. 10.1200/JCO.2009.26.2543, 20351327.
4. Bradley JD, Moughan J, Graham MV, Byhardt R, Govindan R, Fowler J, Purdy JA, Michalski JM, Gore E, Choy H. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 2010, 77:367-372. 10.1016/j.ijrobp.2009.04.029, 2869096, 20457350.
5. Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, Garces YI, Shahidi H, Tschetter LK, Schaefer PL, Adjei A, Jett J. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 65:1106-1111. 10.1016/j.ijrobp.2006.02.046, 16730134.
6. Bradley JD, Paulus R, Komaki R. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy cetuximab for stage IIIa/IIIb non-small cell lung cancer: Preliminary findings on radiation dose in RTOG 0617 2011, Miami Beach, Florida: Presented at the 53rd ASTRO Annual Meeting.
7. Mehta M, Scrimger R, Mackie R, Paliwal B, Chappell R, Fowler J. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001, 49:23-33. 10.1016/S0360-3016(00)01374-2, 11163494.
8. Salama JK, Vokes EE. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol 2013, 31:1029-1038. 10.1200/JCO.2012.44.5064, 23401449.
9. Uitterhoeve AL, Belderbos JS, Koolen MG, van der Vaart PJ, Rodrigus PT, Benraadt J, Koning CC, González González D, Bartelink H. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: Results of the EORTC 08912 phase I/II study: European Organization for Research and Treatment of Cancer. Eur J Cancer 2000, 36:592-600. 10.1016/S0959-8049(99)00315-9, 10738123.
10. Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, Price A, van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G, Koning C, EORTC LCG and RT Group Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007, 43:114-121. 10.1016/j.ejca.2006.09.005, 17084621, EORTC LCG and RT Group.
11. Maguire J, McMenemin R, O'Rourke N. SOCCAR: sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC. J Clin Oncol 2011, 29:462s. suppl; abstr 7039.
12. Carruthers R, O'Rourke N, Mohammed N, Hicks J, Brisbane. Toxicity of hypofractionated accelerated radiotherapy concurrent with chemotherapy for non-small cell carcinoma of the lung. Clin Oncol (R Coll Radiol) 2011, 23:561-562.
13. Cho KH, Ahn SJ, Pyo HR, Kim KS, Kim YC, Moon SH, Han JY, Kim HT, Koom WS, Lee JS. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study. Int J Radiat Oncol Biol Phys 2009, 74:1397-1404. 10.1016/j.ijrobp.2008.10.020, 19117690.
14. Osti MF, Agolli L, Valeriani M, Falco T, Bracci S, De Sanctis V, Enrici RM. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013, 85(3):e157-163. 10.1016/j.ijrobp.2012.10.012, 23182393.
15. Xie SX, Li WX, Lin YR, Zou WC. Three-dimensional conformal hypofractionated radiotherapy for non-small -cell lung cancer. China Oncology 2006, 12:1034-1037. in Chinese.
16. Kim B, Ahn YC, Lim do H, Nam HR. High-dose thoracic radiation therapy at 3.0 Gy/fraction in inoperable stage I/II non-small cell lung cancer. Jpn J Clin Oncol 2008, 38:92-98. 10.1093/jjco/hym159, 18267986.
17. Xie SX, Li WX, Zeng ZJ, Chen YR. Escalated dose trial with hypofractionated three-dimensional conformal radiation therapy for non-small cell lung cancer. Chin J Clin Oncol 2009, 36:972-975. (in Chinese).
18. Zhu GY, Xia TY, Wang LH, Gao XS, Wang JJ, Li GF, Zhang FQ, Ma L, Li YX, Xu B. Consensus and controversies on delineation of radiotherapy target volume for patients with non-small cell lung cancer. Chin J Radiat Oncol 2008, 17:432-436. (in Chinese).
19. Lin Q, Liu Y, Wang N, Huang Y, Ge X, Ren X, Chen X, Hu J, Guo Z, Zhao Y, Asaumi J. A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer. J Radiat Res 2013, 54:126-134. 10.1093/jrr/rrs081, 3534282, 22988282.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
21. Beli I, Koukourakis G, Platoni K, Tolia M, Kelekis N, Kouvaris J, Syrigos C, Mystakidou K, Varveris C, Kouloulias V. Hypofractionated radiotherapy in non small cell lung cancer: a review of the current literature. Rev Recent Clin Trials 2010, 5:103-111. 10.2174/157488710791233608, 20423316.
22. Fowler JF, Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 2000, 46:516-517. 10.1016/S0360-3016(99)00364-8, 10661362.
23. Fletcher GH. Clinical dose response curves of human malignant epithelial tumors. Br J Radiol 1973, 46:151.
24. Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C, Kalemkerian GP, Hayman JA. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005, 63:324-333. 10.1016/j.ijrobp.2005.02.010, 16168827.
25. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K, Araki T. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2(7 Suppl 3):S94-100.
26. Thirion P, Holmberg O, Collins CD, O'Shea C, Moriarty M, Pomeroy M, O'Sullivan C, Buckney S, Armstrong J. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. Radiother Oncol 2004, 71:163-166. 10.1016/j.radonc.2003.09.006, 15110449.
27. Ohri N, Dicker AP, Lawrence YR. Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. Int J Radiat Oncol Biol Phys 2012, 83:385-393. 10.1016/j.ijrobp.2011.06.1990, 22265460.
28. Zhu ZF, Fan M, Wu KL, Zhao KL, Yang HJ, Chen GY, Jiang GL, Wang LJ, Zhao S, Fu XL. A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer. Radiother Oncol 2011, 98:304-308. 10.1016/j.radonc.2011.01.022, 21345508.
29. Glynne-Jones R, Sebag-Montefiore D. Chemoradiation schedules-what radiotherapy?. Eur J Cancer 2002, 38:258-269. 10.1016/S0959-8049(01)00370-7, 11803142.
30. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
31. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004, 46:87-98. 10.1016/j.lungcan.2004.03.004, 15364136.
32. Lin Q, Wang J, Liu Y, Su H, Wang N, Huang Y, Liu CX, Zhang P, Zhao Y, Chen K. High-dose 3-dimensional conformal radiotherapy with concomitant vinorelbine plus carboplatin in patients with non-small cell lung cancer: a feasibility study. Oncol Lett 2011, 2(4):669-674. 3406461, 22848247.
33. Curran WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103:1452-1460. 10.1093/jnci/djr325, 3186782, 21903745.
34. Fournel P, Robinet G, Thomas P, Souquet PJ, Léna H, Vergnenégre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daurés JP, Mornex F, Pérol M. Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 study. J Clin Oncol 2005, 23:5910-5917. 10.1200/JCO.2005.03.070, 16087956.
35. Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Ungaro P, Sleeper A, Green M, Miller AA, Vokes EE. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008, 26:2457-2463. 10.1200/JCO.2007.14.7371, 18487565.
36. Harada H, Nishio M, Murakami H, Ohyanagi F, Kozuka T, Ishikura S, Naito T, Kaira K, Takahashi T, Horiike A, Nishimura T, Yamamoto N. Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent s-1 and cisplatin for inoperable stage iii non-small-cell lung cancer. Clin Lung Cancer 2013, 14:440-445. 10.1016/j.cllc.2013.01.003, 23540866.
37. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial: CHART Steering Committee. Lancet 1997, 350:161-165. 10.1016/S0140-6736(97)06305-8, 9250182.
38. Belderbos J, Heemsbergen W, Hoogeman M, Pengel K, Rossi M, Lebesque J. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol 2005, 75:157-164. 10.1016/j.radonc.2005.03.021, 15890421.
39. Bradley J, Deasy JO, Bentzen S, El Naqa I. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys 2004, 58:1106-1113. 10.1016/j.ijrobp.2003.09.080, 15001251.
40. Singh AK, Lockett MA, Bradley JD. Predictors of radiationinduced esophageal toxicity in patients with nonsmall-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003, 55:337-341. 10.1016/S0360-3016(02)03937-8, 12527046.
41. Maguire PD, Sibley GS, Zhou SM, Jamieson TA, Light KL, Antoine PA, Herndon JE, Anscher MS, Marks LB. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 1999, 45:97-103. 10.1016/S0360-3016(99)00163-7, 10477012.
42. Werner-Wasik M, Pequignot E, Leeper D, Hauck W, Curran W. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariable analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 2000, 48:689-696. 10.1016/S0360-3016(00)00699-4, 11020565.
43. van Baardwijk A, Bosmans G, Boersma L, Wanders S, Dekker A, Dingemans AM, Bootsma G, Geraedts W, Pitz C, Simons J, Lambin P, De Ruysscher D. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys 2008, 71:1394-1401. 10.1016/j.ijrobp.2007.11.070, 18258380.